Diagonal Therapeutics Secures $125M Series B to Advance Pipeline
CAMBRIDGE, Mass. | January 8, 2026 — Diagonal Therapeutics, a biotechnology company developing disease-modifying clustering antibody therapies, announced the...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CAMBRIDGE, Mass. | January 8, 2026 — Diagonal Therapeutics, a biotechnology company developing disease-modifying clustering antibody therapies, announced the...
SAN DIEGO | January 8, 2026 — Just – Evotec Biologics, a collaboration between Evotec SE and Just –...
Palo Alto, Calif., October 28, 2025 — Greenstone Biosciences announced a strategic collaboration with NVIDIA to develop next-generation AI-driven...
